

The role of HIV-DNA testing in clinical practice

Gabriella d'Ettore¹, Lorenzo Zaffiri¹, Giancarlo Ceccarelli¹, Claudio M. Mastroianni², Vincenzo Vullo¹

¹Department of Tropical and Infectious Diseases "Sapienza" University of Rome;

²Department of Infectious Diseases, "Sapienza" University of Rome, Polo Pontino

SUMMARY

HIV-1 RNA levels and CD4+T lymphocyte counts are currently the standard markers used in clinical practice for the management of HIV infection. Nowadays it is also possible to monitor the evolution of HIV infection by measuring HIV-DNA. This measurement is a useful new clinical marker mainly been used to date in experimental evaluations. HIV-DNA can be detected in lymphoid tissues and in PBMC even during powerful and prolonged antiretroviral therapy. Understanding the HIV-DNA marker, together with all the other standard markers used in clinical practice, is now essential in monitoring the progression of the infection. Furthermore, the measurement of the levels of HIV-DNA in different stages could indicate the spread of the infection reflecting the ability of antiretroviral therapy to purge reservoirs. This review highlights the importance of evaluating the HIV-DNA load which could provide an indirect estimate of the quantity of reservoirs. This is an important factor in establishing the progression of infection, sequencing therapy and predicting the failure of antiretroviral therapy at a early stage.

KEY WORDS: HIV-DNA, Reservoirs, Viral marker

Received June 1, 2009

Accepted October 2, 2009

INTRODUCTION

The introduction of highly active antiretroviral therapy (HAART) has not only dramatically decreased morbidity and mortality in AIDS, but it has also transformed HIV infection into a man-

ageable chronic condition (Burton *et al.* 2005; Mocroft *et al.* 2000; Palella *et al.*, 1998).

The study of HIV-DNA load could be useful to improve the life-long treatment of HIV infection. HIV-disease requires frequent virological and immunological monitoring to detect early therapeutic failures and to follow up the evolution of resistant viral variants (Mellors *et al.*, 2007). The CD4+ T lymphocyte count and the HIV-RNA load have been the standard markers used in clinical practice for the management and monitoring of HIV-infected patients (Paolucci *et al.*, 2001).

The CD4+ T-cell count provides knowledge on the patient's immunological status and HIV-RNA load gives information on the degree of viral replication at the time of the assay. The levels of viral load (VL) could vary because of the influence of several factors linked to both the virus and the host such as viral fitness and immunoactivation. Until recently, no markers could be used routinely to quantify the viral load in HIV reservoirs. Now, the evolution and dynamics of HIV infection can be evaluated by measuring HIV-DNA load, a more reliable virological marker providing information on the amount of virus in host immune tissues.

ABBREVIATIONS

cART: combined antiretroviral therapy
 HAART: highly active antiretroviral therapy
 HAD: HIV-associated dementia
 LTR: long terminal repeat
 PIC: pre-integration complex
 PI: protease inhibitor
 RR: relative risk
 VL: viral load

Corresponding author

Gabriella d'Ettore

Department of Tropical and Infectious Diseases

"La Sapienza" University of Rome

Viale del Policlinico, 155 - 00161 Rome, Italy

E-mail: gabriella.dettore@uniroma1.it

Moreover HIV-DNA load may give an estimate on the number of infected cells, including CD4⁺ T lymphocytes, and on the size of the viral reservoir from which infectious virions can potentially be released (Pomerantz 2003; Re *et al.*, 2006). Persistence of a large number of latently-infected cells poses a major obstacle to the eradication of HIV infection by antiretroviral treatment (Finzi *et al.*, 1997). In fact, it is evident now that, even in HAART-treated patients with sustained viral suppression, HIV cannot be eradicated because of the presence of long-lived, infected memory CD4⁺ T cells representing a viral reservoir, and HIV-1 latency (Chun *et al.*, 1998; Dornadula *et al.* 2001). Secondly, it can be useful in clinical management in predicting very early failures and in sequencing the combined antiretroviral therapy (Dornadula *et al.*, 1999; Bell *et al.*, 2001).

While measuring the HIV-DNA load is now easier than in the past through the use of real-time PCR, there is no commercial test available and the assay has to be established in house and is therefore not easy to implement in a routine diagnostic setting.

This review highlights the potential role of HIV-DNA load in clinical practice taking into consideration the need to implement more standardized tests in routine diagnostic settings.

Different forms of HIV-DNA

Different types of HIV-DNA have been found in infected cells: linear integrated, linear and circular non-integrated forms of HIV-DNA are identified during a productive infection.

Following entry into host cells, the reverse transcriptase (RT) enzyme converts the viral genome from RNA into a linear double-stranded DNA (dsDNA) (Gomez and Hope 2005; Swiggard *et al.*, 2005).

Through the pre-integration complex (PIC), the newly-formed HIV-DNA will enter the nucleus but not all of it will become integrated into the host genome (Pauza *et al.*, 1994). In the nucleus the final product of the integration process will be the linear integrated HIV-DNA, also called HIV-provirus. HIV-provirus is fundamental to the transcription process and virus production, but it also gives stability to the retroviral genome integrated in the host cells. Depending on the state of infected CD4⁺ T cells, HIV-provirus could take two different pathways. It could be actively tran-

scribed in them if they are activated or it could remain in a latent state if they revert back to a quiescent state and become memory CD4⁺ T cells (Robinson and Zinkus 1990). The stable, integrated and transcriptionally silent provirus is not affected by antiretroviral therapy.

The other forms of HIV-DNA can be considered side products and they are represented by linear and circular non-integrated forms distinguished by the presence of a long terminal repeat (LTR) sequence in a 1-LTR circle or 2-LTR circle. A huge quantity of non-integrated HIV-DNA in the nuclei of infected cells is generally believed to be the result of multiple infections (Bukrinsky *et al.*, 1991; Teo *et al.*, 1997).

In both resting and activated CD4⁺ T cells, non-integrated HIV-DNA represents the most prevalent form of HIV-DNA and a large amount of it can be detected in vivo. Moreover, most of HIV-DNA appears to be in non-integrated forms particularly in those patients with detectable VL in the plasma (Blankson *et al.* 2000; Sharkey *et al.*, 2000; Butler *et al.*, 2001).

Although these forms of HIV-DNA are labile intermediates, their detection could be indicative of a productive infection. Sharkey *et al.* suggested that the episomal 2-LTR form of HIV-DNA can be used as the marker of recent infection or ongoing replication in those patients with undetectable viraemia under HAART (O'Doherty *et al.*, 2002).

Although it is possible to distinguish between the integrated and non-integrated forms of HIV-DNA (Brussel *et al.*, 2005; Vandergraaff *et al.*, 2001; Alcamí *et al.*, 1995), so far there has been no standardized methods to measure the number of cells with integrated HIV-DNA.

Due to difficulties in different techniques, it still seems feasible only in a few major laboratories. The recombination forms of non-integrated HIV-DNA cannot generate a productive infection but they can express the viral genes by being actively transcribed.

Their role in the pathogenesis of HIV infection is still unclear (Chen *et al.*, 1997). Transcription is promoted by the presence in LTR sequences of promoter and enhancer elements which present a high affinity for several cellular transcription factors, such as NF- κ B (Nabel and Baltimore 1987; Stevenson *et al.*, 1990). The role of these viral transcripts also remains unclear even though

their presence has been documented in vitro early after HIV infection (Stevenson and Haggerty *et al.*, 1990). However, Wu *et al.* suggested that they could play an important role in generating a productive HIV infection (Wu *et al.*, 2004).

HIV-DNA: reservoir establishment and persistence

Persistence of the virus depends on the long-term survival of a pool of infected cells called resting CD4+ T lymphocytes which constitute the HIV reservoir.

The frequency of latently infected cells is ~ 1 in 10^6 resting CD4 T cells. This reservoir is generated early during an acute infection by reversion of the infected CD4+ T cells into quiescent memory lymphocytes. These resting CD4+ T cells are transcriptionally silent but they can produce new infectious virions when activated again (Haggerty *et al.*, 2001; Brooks *et al.*, 2001; Chun *et al.* 1997). To date, the major obstacle to eradication of HIV infection is HIV-DNA archived in the life-long memory of CD4+ T lymphocytes (Wong *et al.* 1997; Zhang *et al.* 1999; Finzi *et al.* 1999). This reservoir could persist despite several years of undetectable viraemia under HAART (Siliciano *et al.* 2003; Strain *et al.* 2003).

Although the mechanisms of persistence remain unclear, the stability of this set of cells can be explained in the following ways (Sedaghat *et al.* 2008). First of all, both the long half-life of resting CD4+ T cells and the possibility of their self-renewal by proliferation may contribute to persistence of this pool of infected cells (Pierson *et al.* 2000). Secondly, the latently-infected cells with harboured transcriptionally-silent HIV-DNA seem to be protected from host immune responses and the cytopathic effects of the virus, thereby further increasing their chances of survival (Ramratnam *et al.* 2000).

Moreover, persistent low level replication or sporadic bursts of replication during HAART (e.g., due to occasional lapses in adherence) can also replenish the reservoirs in people who appear to be treated successfully (Chun *et al.* 2005). The residual viral replication could be responsible for continuous cross-infection between the resting and activated T-cell compartments and therefore for resetting the size of the HIV reservoir (Havlir *et al.* 2001). Finally, we could hypothesize that intermittent phases of viraemia called "blips" could

also continuously refill the reservoir (Mira *et al.* 2002; Jones *et al.* 2007; Ramratnam *et al.* 2004). Although eradication of HIV infection seems remotely possible with currently available drugs, new therapeutic strategies such as intensification (Persaud *et al.* 2000) and addition of new antiretroviral drugs to target the reservoirs could further reduce the levels of ongoing replication and the size of the HIV reservoir (Shen and Siliciano 2008).

One more good reason to study stably-integrated HIV-DNA in the infected cells is that we may consider it a large viral library containing all quasi-species, including the original wild-type and the resistant variant strains generated during suboptimal regimens (Ruff *et al.* 2002). Boni *et al.* analyzed HIV-1 drug-resistant variants in plasma and peripheral blood mononuclear cells in 56 therapy-naive patients with recent and chronic infection to assess the prevalence of mutations associated with drug resistance and compare cell-free and cell-associated strains. Their results showed a different resistance profile between plasma and PBMC compartments and the authors concluded suggesting the PBMC compartment be explored before of the first line of treatment (Bon *et al.* 2007).

There is a direct correlation between the number of integrated sequences of mutant viral strains and the exposure time to HAART in those patients with a history of suboptimal therapy or with cycles of discontinued therapy (Silva *et al.* 2006). Interestingly, in the absence of drug influence, resurgence of the wild-type is observed in patients with drug-resistant strains in resting CD4+ T cells and also in those with undetectable viraemia who have started structured interruption of antiretroviral therapy (Deeks *et al.* 2001). In fact, the wild-type presents better fitness than the mutant strains and therefore it replicates faster and more effectively. The importance of evaluating archived resistant strains was also confirmed by the French PRIMO cohort study in which virological failure was observed in three patients who, despite empirical HAART, presented resistant strains in the reservoir following primary HIV infection (Ghosn *et al.* 2006).

The archived drug-resistant strains represent a major restriction on treatment options. Further, in the absence of a universally-accepted method of determining different genotypes of the virus in

the reservoir, those drug-resistant strains may cause future failures, not only in patients with no stable control over viral replication in spite of the treatment, but also in new patients infected directly by mutant strains.

HIV-DNA: role in the monitoring of the therapeutic strategies

The study of HIV-1 DNA could be considered another important marker in clinical practice, especially in evaluating the sequencing of anti-retroviral therapy in every stage of the HIV infection.

There are several treatment strategies that could benefit from an assessment of HIV-DNA including: primary infection, chronic infection with simplification or structured interruption strategies. In addition, HIV-DNA testing could also consider that similar considerations apply to patients with a complex treatment history, in whom the assessment of previously archived resistance may be helpful. In order to avoid the subsequent appearance of resistant viral strains and treatment failures, the exact time to begin each strategy must be established with the utmost care. Currently, based on the US Department of Health and Human Services guidelines, CD4+ T-cell count and HIV-RNA load are the two markers used to decide when to start treatment and how to monitor the effectiveness of HAART (DHHS Panel on Antiretroviral Guidelines for Adult and Adolescents 2009; Rosenberg *et al.* 2000). The persistence of HIV-DNA in resting CD4+ T cells emphasizes the usefulness of a new viral marker besides HIV-RNA load in the follow-up of HIV-infected patients.

Primary infection

HIV-DNA load could provide more information on the state of HIV-1 infection and the benefits of an early HAART since it has been demonstrated that low CD4+ T-cell count and high HIV-DNA load during primary infection lead to rapid progression to AIDS and increase in mortality (Goujard *et al.* 2006).

An important focus on HAART is the benefits of an early treatment during primary infection. The current guidelines still remain vague on the importance of prompt treatment in those patients with seroconversion <6 months earlier. Although early treatment appears to be effective in con-

trolling viral replication, gain in CD4+ T-cell count and delay in disease progression to AIDS (Cossarizza *et al.* 2004; Strain *et al.* 2005), more data are needed to better address the issue on how truly tangible the advantages are. In this connection, HIV-DNA load could provide more information on the state of HIV-1 infection and the benefits of an early HAART. In their study, Garrigue *et al.* reported the different pathways that HIV-RNA and the HIV-DNA take in plasma and latently-infected cells in patients with primary infection under HAART.

The authors observed, in general, a gradual decrease in the levels of HIV-DNA and HIV-RNA in PBMC in patients with primary infection after 18-month follow-up with undetectable HIV-RNA in the plasma. In particular, HIV-DNA load decreased by 1 log and was detectable in 92.3% of patients whereas HIV-RNA load decreased by 3.6 log with a sharp decline in PBMC in the first 6 months followed by a plateau (Garrigue *et al.* 2000).

In our opinion, knowledge of the exact amount of HIV-DNA and monitoring the decay of HIV-DNA load after first line therapy could provide better data for selection of subsequent therapeutic strategies, such as simplification or interruption, than the values of CD4+ T-cell count and HIV-RNA load.

Chronic infection

The introduction of HAART in clinical practice has brought great benefits to patients with chronic HIV infection as shown by a drastic decline in opportunistic infections, hospitalizations, etc. (Mocroft *et al.* 2003).

However, HAART has also presented new challenges with regard to drug toxicity in the management of HIV-infected patients. As the immunological and virological benefits have to be weighed against the risks of prolonged exposure to potentially toxic drugs, it is never easy to establish when to initiate HAART. From HIV-DNA load new data could be extrapolated to clinical progression and it could help clinicians in making decisions on the right time to initiate HAART or to change therapeutic strategies. It was suggested before that HIV-DNA load be used as an independent marker of disease progression. In fact, Kostrikis *et al.* demonstrated that five years after infection patients who had started HAART with

CD4 + T-cell count $<350 \mu\text{L}$ and HIV-DNA load $<3 \log_{10}$ copies/ 10^6 PBMCs presented a lower risk of clinical progression to AIDS than those with CD4+ T-cell count $>350 \mu\text{L}$ and HIV-DNA load $>3 \log_{10}$ copies/ 10^6 PBMCs (Kostrikis *et al.* 2002). Rouzioux *et al.* showed in an elegant study that the risk of clinical progression to AIDS could be better described by HIV-DNA load rather than by other markers (Rouzioux *et al.* 2005). In fact, they reported that for 383 patients at the time of seroconversion the crude RR of clinical progression to AIDS was 5.80 for each $1\text{-}\log_{10}$ increase in HIV-DNA load whereas it was 2.97 for each $1\text{-}\log_{10}$ increase in HIV-RNA load and 1.25 for each $100\text{-cell}/\mu\text{L}$ decrease in CD4+ T-cell count. Perhaps an extended evaluation of CD4+ T-cell count, HIV-RNA load and HIV-DNA load in each patient could give the best estimate on both the state of viral infection and the risk of disease progression.

VL is not always useful in evaluating the risk of developing diseases linked to HIV infection. In a condition of undetectable VL, recent data in the literature show that approximately 10.1/100 person year developed HIV-associated dementia (HAD) (Shiramizu *et al.* 2007; Langford *et al.* 2006). This illustrates the virological and immunological status change in different compartments during HIV infection.

The possibility that monocytes/macrophages could harbour different forms of HIV-DNA increases speculation over the usefulness of this marker in evaluating the evolution of infection, including AIDS-related neurological conditions. The latest paper by Shiramizu *et al.* shows that the amount of HIV-DNA in peripheral blood mononuclear cells is correlated to the neurocognitive disorders.

In particular they conducted a longitudinal study to examine HIV-associated neurocognitive disorders in the Hawaii Aging with HIV Cohort that includes older >50 years old and younger 20-39 years old patients. In addition, the participants of the study were divided into: normal cognition, minor cognitive motor disorder and HIV-1 associated dementia. The levels of HIV-RNA and the CD4 cell count were similar in the three groups, whereas HIV-DNA levels differed significantly among all three groups. In particular, a correlation was found between circulating levels of HIV-DNA and HIV-1 associated neurocognitive disor-

ders. To better understand this result and to exclude a possible correlation between HIV-DNA levels and HIV-RNA the measurement of HIV-DNA was repeated in patients with undetectable levels of HIV-RNA. The results confirmed that the levels of HIV-DNA are correlated to the neurocognitive status.

The authors emphasized that all patients took therapy with no differences in CNS penetration. These findings suggest that HIV-DNA has an important role in the pathogenesis of neurologic disorders and that it is a key marker in the follow up of HIV infection (Shiramizu *et al.* 2009).

Moreover, HIV-DNA load could give clinicians an opportunity to initiate HAART in those patients whose immune status falls in the so-called "grey zone". There is a slower clinical progression to AIDS in those with CD4+ T-cell count $<350 \mu\text{L}$ and HIV-DNA load $<3.2 \log$ than in the ones with CD4+ T-cell count $>350 \mu\text{L}$ and HIV-DNA load $>3.2 \log$. (Kostrikis *et al.* 2002). This result suggests that even in the presence of high CD4+ T-cell counts, HIV-DNA load of $3.2 \log$ could represent the threshold at which HAART could be started. Knowledge of HIV-DNA load helps in evaluating the virological and immunological aspects of each patient necessary to establish the right moment to initiate HAART and also to better assess the future therapeutic scenario.

HIV-DNA load could also become a tool to predict the long-term success of HAART in naïve patients under the initial therapy, perhaps as a marker of virological failure in those with initial viral response to therapy. Several studies indicated that the quantification of different forms of HIV-DNA in PBMC could provide information on the prolonged effectiveness of HAART. In particular, a small follow-up study on 51 patients indicated that HIV-DNA load was the only predictive parameter of virological rebound in the group of non-responders.

In fact, baseline HIV-DNA load was higher in the patients with virological failure to HAART than in those with sustained undetectable viraemia under HAART. The total decay of integrated HIV-DNA and non-integrated 2-LTR HIV-DNA forms could be considered complete success of the antiretroviral therapy in those patients with persistent undetectable HIV-RNA load under HAART (Hatzakis *et al.* 2004; Gillim-Ross *et al.* 2005; McDermott *et al.* 2005; Havlir *et al.* 2005). In ad-

dition, HIV-DNA load was found to be the only predictive marker of residual viraemia in HAART. We may hypothesize that HIV-DNA load gives indirect information on the capacity of the virus to infect new cells which contributes to persistence of the HIV latent reservoir (Pellegrin *et al.* 2003). Decrease in HIV-DNA load ought to be considered the cornerstone of therapeutic sequencing. In fact, lower HIV-DNA loads are predictive of sustained undetectability of plasma viraemia in those patients switching from a protease inhibitor (PI)-based regimen to simplified therapy (d'Ettorre *et al.* 2007; Viard *et al.* 2004; Burton *et al.* 2005).

This therapeutic strategy could be a safe and attractive option to certain groups of patients under certain circumstances because it not only improves adherence but also reduces the toxicity of antiretroviral drugs.

It was also observed in the structured treatment interruption studies that higher HIV-DNA loads at the beginning of interruption of drug intake was later reflected in faster increases in HIV-RNA load as well as HIV-DNA load with a loss of previous virological gains obtained with HAART (Lewin *et al.* 2008). HIV-DNA load can be useful as a prognostic factor of long-term CD4+count-guided interruption of antiretroviral treatment. Sarmati *et al.* found a virological and immunological score associated with treatment interruption of more

than 180 days that include four parameters: nadir CD4 cell count >269 cells/mm³, baseline CD4+ cell count >675 cells/mm³, baseline proviral HIV-DNA levels of <323 cp/10⁶ PBMC and CD4+cells count at 14 days of interruption >564cells/mm³. They conducted a pilot prospective, open label, multicenter trial comprising 62 HIV-seropositive patients who decided to interrupt therapy after two or more years of successful HAART and observed at multivariate regression analysis that HIV-DNA level of 323 cp/10⁶ PBMC and a CD4 count at day 14 after interruption more than 564 cells/mm³ were independently associated to a reduced risk of restarting therapy. In addition they found that patients with a nadir of CD4 cell count >269 cell/mm³ at baseline, proviral HIV-DNA levels >323 cp/10⁶ PBMC and CD4 at 14 days after interruption, >564 cell/mm³ were more likely to remain drug-free for a long period of time (Sarmati *et al.* 2009).

In addition, monitoring the HIV-DNA load could also be useful to obtain information on the consequence of the HAART interruption on viral reservoirs. The study conducted by Palmisano *et al.* on 37 HIV positive subjects enrolled in the Istituto Superiore di Sanità-Pulsed antiretroviral Therapy (ISS-PART) clinical trial compared 24 months of intermittent (arm B) versus continuous (arm A) HAART in chronic HIV infection. The authors found that fixed-time treatment interrup-




FIGURE 1 - Model of potential uses of HIV-DNA in the clinical management of HIV infection.

tion in patients who had reached a steady-state level of HIV-DNA has a negligible effect on total HIV-1 DNA and on the number of provirus infected cells. These considerations suggest that the number of HIV-1 DNA copies corresponds to the number of both resting both activated infected cells and thus the value of HIV-DNA can be considered a marker of viral burden (Palmisano *et al.* 2008).

It is not uncommon to witness under HAART some important instances in which patients have several blips of viraemia and show no sign of gain in CD4+ T-cell count.

Under these circumstances, a crucial decision on either changing or intensifying the therapy needs to be made to avoid accumulation of resistant viral strains and useless administration of new drugs. However, this kind of patient is not defined as a complete failure to the therapy. In such cases, HIV-DNA load can provide an indication on whether to change or intensify the current anti-retroviral therapy.

Intensification of the therapy in patients with several viral blips helps us to reach a decay of latent cells in the HIV reservoir, thereby reducing the state of transient viraemia (Jones and Perelson 2007). Altogether these data clearly substantiate the importance of observing progressive levels of HIV-DNA during the management of different phases of HIV infection.

Therefore, HIV-DNA load provides clinicians with a broader panorama of data previously not available with CD4+ T-cell count and HIV-RNA load which only give information on rapid and partial changes. The values of this new viral marker at different times in the clinical history of an HIV-infected patient should be integrated with the previous clinical data for better evaluation of the disease and for better control of the therapeutic efficacy.

HIV-DNA load is an important marker on which the management of antiretroviral treatment for each HIV-infected patient should be based. Evaluation of this marker at different stages in the history of infection, and consequently information on the size of HIV reservoir, can help clinicians to choose the best strategies and to control the progression of HIV infection (Figure 1). In addition, the decrease in HIV-DNA load would facilitate patients in optimizing various therapeutic strategies such as intensification, simplification

and structured interruption of therapy. In future, this research tool should become a part of clinical practice in refining therapeutic strategies.

REFERENCES

- ALCAMÍ J., LAÍN DE LERA T., FOLGUEIRA L., PEDRAZA M.A., JACQUÉ J.M., BACHELERIE F., NORIEGA A.R., HAY R.T., HARRICH D., GAYNOR R.B., VIRELIZIER J.L., ARENZANA-SEISDEDOS F. (1995). Absolute dependence on kappa B responsive elements for initiation and Tat-mediated amplification of HIV transcription in blood CD4 T lymphocytes. *EMBO J.* **14** (7), 1552-1560.
- BELL P., MONTANER L.J., MAUL G.G. (2001). Accumulation and intranuclear distribution of unintegrated human immunodeficiency virus type 1 DNA. *J. Virol.* **75** (16), 7683-7691.
- BLANKSON J.N., FINZI D., PIERSON T.C., SABUNDAYO B.P., CHADWICK K., MARGOLICK J.B., QUINN T.C., SILICIANO R.F. (2000). Biphasic decay of latently infected CD4+ T cells in acute human immunodeficiency virus type 1 infection. *J. Infect. Dis.* **182** (6), 1636-1642.
- BON I., ALESSANDRINI F., BORDERI M., GORINI R., RE M.C. (2007). Analysis of HIV-1 drug-resistant variants in plasma and peripheral blood mononuclear cells from untreated individuals: implications for clinical management. *New Microbiol.* **30** (3), 313-317.
- BROOKS D.G., KITCHEN S.G., KITCHEN C.M., SCRIPTURE-ADAMS D.D., ZACK J.A. (2001). Generation of HIV latency during thymopoiesis. *Nat. Med.* **7** (4): 459-464.
- BRUSSEL A., DELELIS O., SONIGO P. (2005). Alu-LTR real-time nested PCR assay for quantifying integrated HIV-1 DNA. *Methods Mol. Biol.* **304**, 139-154.
- BUKRINSKY M.I., STANWICK T.L., DEMPSEY M.P., STEVENSON M., QUIESCENT T. (1991). Lymphocytes as an inducible virus reservoir in HIV-1 infection. *Science.* **254**, 423- 427
- BURTON C.T., NELSON M.R., HAY P., GAZZARD B.G., GOTCH F.M., IMAMI N. (2005). Immunological and virological consequences of patient-directed antiretroviral therapy interruption during chronic HIV-1 infection. *Clin. Exp. Immunol.* **142** (2), 354-361.
- BUTLER S.L., HANSEN M.S., BUSHMAN F.D. (2001). A quantitative assay for HIV DNA integration in vivo. *Nat Med.* **7** (5), 631-634.
- CHEN B.K., FEINBERG M.B., BALTIMORE D. (1997). The kappaB sites in the human immunodeficiency virus type 1 long terminal repeat enhance virus replication yet are not absolutely required for viral growth. *J. Virol.* **71** (7), 5495-5504.
- CHUN T.W., ENGEL D., BERREY M.M., SHEA T., COREY L., FAUCI A.S. (1998). Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. *Proc. Natl. Acad. Sci. USA.* **95** (15), 8869-8873.

- CHUN T.W., NICKLE D.C., JUSTEMENT J.S., LARGE D., SEMERJIAN A., CURLIN M.E., O'SHEA M.A., HALLAHAN C.W., DAUCHER M., WARD D.J., MOIR S., MULLINS J.I., KOVACS C., FAUCI A.S. (2005). HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. *J. Clin. Invest.* **115** (11), 3250-3255.
- CHUN T.W., STUYVER L., MIZELL S.B., EHLEH L.A., MICAN J.A., BASELER M., LLOYD A.L., NOWAK M.A., FAUCI A.S. (1997). Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. *Proc. Natl. Acad. Sci. USA.* **94** (24), 13193-13197.
- COSSARIZZA A., POCCIA F., AGRATI C., D'OFFIZI G., BUGARINI R., PINTI M., BORGHI V., MUSSINI C., ESPOSITO R., IPPOLITO G., NARCISO P. (2004). Highly active anti-retroviral therapy restores CD4+ Vbeta T-cell repertoire in patients with primary acute HIV infection but not in treatment-naive HIV+ patients with severe chronic infection. *J. Acquir. Immune Defic. Syndr.* **35**, 213-222.
- DEEKS S.G., WRIN T., LIEGLER T., HOH R., HAYDEN M., BARBOUR J.D., HELLMANN N.S., PETROPOULOS C.J., MCCUNE J.M., HELLERSTEIN M.K., GRANT R.M. (2001). Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viraemia. *N. Engl. J. Med.* **344** (7), 472-480.
- D'ETTORRE G., ZAFFIRI L., CECCARELLI G., ANDREOTTI M., MASSETTI A.P., VELLA S., MASTROIANNI C.M., VULLO V. (2007). Simplified maintenance therapy with abacavir/lamivudine/zidovudine plus tenofovir after sustained HIV load suppression: four years of follow-up. *HIV Clin. Trials.* **8** (3): 182-188.
- DHHS PANEL ON ANTIRETROVIRAL GUIDELINES FOR ADULT AND ADOLESCENTS. (2009). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 1-128.
- DORNADULA G., NUNNARI G., VANELLA M., ROMAN J., BABINCHAK T., DE SIMONE J., STERN J., BRAFFMAN M., ZHANG H., POMERANTZ R.J. (2001). Human immunodeficiency virus type 1-infected persons with residual disease and virus reservoirs on suppressive highly active antiretroviral therapy can be stratified into relevant virologic and immunologic subgroups. *J. Infect. Dis.* **183** (11), 1682-1687.
- DORNADULA G., ZHANG H., VANUITERT B., STERN J., LIVORNESE L. JR, INGERMAN M.J., WITEK J., KEDANIS R.J., NATKIN J., DE SIMONE J., POMERANTZ R.J. (1999). Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. *JAMA.* **282** (17), 1627-1632.
- FINZI D., BLANKSON J., SILICIANO J.D., MARGOLICK J.B., CHADWICK K., PIERSON T., SMITH K., LISZIEWICZ J., LORI F., FLEXNER C., QUINN T.C., CHAISSON R.E., ROSENBERG E., WALKER B., GANGE S., GALLANT J., SILICIANO R.F. (1999). Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. *Nat. Med.* **5** (5), 512-517.
- FINZI D., HERMANKOVA M., PIERSON T., CARRUTH L.M., BUCK C., CHAISSON R.E., QUINN T.C., CHADWICK K., MARGOLICK J., BROOKMEYER R., GALLANT J., MARKOWITZ M., HO D.D., RICHMANN D.D., SILICIANO R.F. (1997). Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. *Science.* **278**, 1295-1300.
- GARRIGUE I., PELLEGRIN I., HOEN B., DUMON B., HARZIC M., SCHRIVE M.H., SERENI D., FLEURY H. (2000). Cell-associated HIV-1-DNA quantitation after highly active antiretroviral therapy-treated primary infection in patients with persistently undetectable plasma HIV-1 RNA. *AIDS.* **14** (18), 2851-2855.
- GHOSH J., PELLEGRIN I., GOUJARD C., DEVEAU C., VIARD J.P., GALIMAND J., HARZIC M., TAMALET C., MEYER L., ROUZIOUX C., CHAIX M.L. (2006). HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time. *AIDS.* **20** (2), 159-170.
- GILLIM-ROSS L., CARA A., KLOTMAN M.E. (2005). HIV-1 extrachromosomal 2-LTR circular DNA is long-lived in human macrophages. *Viral. Immunol.* **18** (1), 190-196.
- GOMEZ C., HOPE T.J. (2005). The ins and outs of HIV replication. *Cell. Microbiol.* **7** (5), 621-626.
- GOUJARD C., BONAREK M., MEYER L., BONNET F., CHAIX M.L., DEVEAU C., SINET M., GALIMAND J., DELFRAISSY J.F., VENET A., ROUZIOUX C., MORLAT P. (2006). CD4 cell count and HIV DNA level are independent predictors of disease progression after primary HIV type 1 infection in untreated patients. *Clin. Infect. Dis.* **42** (5), 709-715.
- HAGGERY C., PITT E., SILICIANO R.F. (2001). The latent reservoir for HIV-1 in resting CD4+ T cells and other viral reservoirs during chronic infection: insights from treatment and treatment-interruption trials. *Curr. Opin. HIV AIDS.* **1**, 62-68.
- HATZAKIS A.E., TOULOUMI G., PANTAZIS N., ANASTASSAPOULOU C.G., KATSAROU O., KARAFOLIDOU A., GOEDERT J.J., KOSTRIKIS L.G. (2004). Cellular HIV-1 DNA load predicts HIV-RNA rebound and the outcome of highly active antiretroviral therapy. *AIDS.* **18** (17), 2261-2267.
- HAVLIR D.V., BASSETT R., LEVITAN D., GILBERT P., TEBAS P., COLLIER A.C., HIRSCH M.S., IGNACIO C., CONDRA J., GÜNTARD H.F., RICHMAN D.D., WONG J.K. (2001). Prevalence and predictive value of intermittent viraemia with combination HIV therapy. *JAMA.* **286** (2), 171-179.
- HAVLIR D.V., KOELSCH K.K., STRAIN M.C., MARGOT N., LU B., IGNACIO C.C., MILLER M.D., WONG J.K. (2005). Predictors of residual viremia in HIV-infected patients successfully treated with efavirenz and lamivudine plus either tenofovir or stavudine. *J. Infect. Dis.* **191** (7), 1164-1168.
- JONES L.E., PERELSON A.S. (2007). Transient viremia,

- plasma viral load, and reservoir replenishment in HIV-Infected patients on antiretroviral therapy. *J. Acquir. Immune Defic. Syndr.* **45** (5), 483-493.
- KOSTRIKIS L.G., TOULOUMI G., KARANICOLAS R., PANTAZIS N., ANASTASSOPOULOU C., KARAFOLIDOU A., GOEDERT J.J., HATZAKIS A. (2002). Quantitation of human immunodeficiency virus type 1 DNA forms with the second template switch in peripheral blood cells predicts disease progression independently of plasma RNA load. *J. Virol.* **76** (20), 10099-10108.
- LANGFORD D., MARQUIE-BECK J., DE ALMEIDA S., LAZZARETTO D., LETENDRE S., GRANT I., MCCUTCHAN J.A., MASLIAH E., ELLIS R.J. (2006). Relationship of antiretroviral treatment to postmortem brain tissue viral load in human immunodeficiency virus-infected patients. *J. Neuro Virol.* **12**, 100-108.
- LEWIN S.R., MURRAY J.M., SOLOMON A., WIGHTMAN F., CAMERON P.U., PURCELL D.J., ZAUNDERS J.J., GREY P., BLOCH M., SMITH D., COOPER D.A., KELLEHER A.D. (2008). Virologic determinants of success after structured treatment interruptions of antiretrovirals in acute HIV-1 infection. *J. Acquir. Immune Defic. Syndr.* **47** (2), 140-147.
- MCDERMOTT J.L., MARTINI I., FERRARI D., BERTELOTTI F., GIACOMAZZI C., MURDACA G., PUPPO F., INDIVERI F., VARNIER O.E. (2005). Decay of human immunodeficiency virus type 1 unintegrated DNA containing two long terminal repeats in infected individuals after 3 to 8 years of sustained control of viremia. *J. Clin. Microbiol.* **43** (10), 5272-5274.
- MELLORS JW, MARGOLICK JB, PHAIR JP, RINNOLDO CR, DETELS R, JACOBSON LP, MUNOZ A. (2007). Prognostic value of HIV-1 RNA, CD4 cell count, and CD4 Cell count slope for progression to AIDS and death in untreated HIV-1 infection. *JAMA.* **297** (21), 2349-2350.
- MIRA J.A., MACÍAS J., NOGALES C., FERNÁNDEZ-RIVERA J., GARCÍA-GARCÍA J.A., RAMOS A., PINEDA J.A. (2002). Transient rebounds of low-level viraemia among HIV-infected patients under HAART are not associated with virological or immunological failure. *Antivir. Ther.* **7** (4), 251-256.
- MOCROFT A., DEVEREUX H., KINLOCH-DE-LOES S., WILSON D., MADGE S., YOULE M., TYRER M., LOVEDAY C., PHILLIPS A.N., JOHNSON M.A. (2000). Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic population. Royal Free Centre for HIV Medicine. *AIDS.* **14** (11), 1545-1552.
- MOCROFT A., LEDERGERBER B., KATLAMA C., KIRK O., REISS P., D'ARMINIO MONFORTE A., KNYSZ B., DIETRICH M., PHILLIPS A.N., LUNDGREN J.D. (2003). Decline in the AIDS and death rates in the EuroSIDA study: an observational study. *Lancet.* **362**, 22-29.
- NABEL G., BALTIMORE D. (1987). An inducible transcription factor activates expression of human immunodeficiency virus in T cells. *Nature.* **326** (6114), 711-713.
- O'DOHERTY U., SWIGGARD W.J., JEYAKUMAR D., MCGAIN D., MALIM M.H. (2002). A sensitive, quantitative assay for human immunodeficiency virus type 1 integration. *J. Virol.* **76** (21), 10942-10950.
- PALELLA F.J. JR, DELANEY K.M., MOORMAN A.C., LOVELESS M.O., FUHRER J., SATTEN G.A., ASCHMAN D.S., HOLMBERG S.D. (1998). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. *N. Engl. J. Med.* **338** (13), 853-860.
- PALMISANO L., GIULIANO M., CHIAROTTI F., ZANCHETTA M., ANDREOTTI M., PIRILLO M.F., RIVA E., ANTONELLI G., DE ROSSI A., VELLA S. (2008). Modification of HIV-1 DNA and provirus infected cells during 24 months of intermittent Highly active antiretroviral therapy. *J. Acquir. Immune Defic. Syndr.* **48** (1), 68-71.
- PAOLUCCI S., BALDANTI F., CAMPANINI G., ZAVATTONI M., CATTANEO E., DOSSENA L., GERNA G. (2001). Analysis of HIV drug-resistant quasispecies in plasma, peripheral blood mononuclear cells and viral isolates from treatment-naive and HAART patients. *J. Med. Virol.* **65** (2), 207-217.
- PAUZA C.D., TRIVEDI P., MCKECHNIE T.S., RICHMAN D.D., GRAZIANO F.M. (1994). 2-LTR circular viral DNA as a marker for human immunodeficiency virus type 1 infection in vivo. *Virology.* **205** (2), 470-478.
- PELLEGRIN I., CAUMONT A., GARRIGUE I., MEREL P., SCHRIVE M.H., FLEURY H., DUPON M., PELLEGRIN J.L., RAGNAUD J.M. (2003). Predictive value of provirus load and DNA human immunodeficiency virus genotype for successful abacavir-based simplified therapy. *J. Infect. Dis.* **187** (1), 38-46.
- PERSAUD D., PIERSON T., RUFF C., FINZI D., CHADWICK K.R., MARGOLICK J.B., RUFF A., HUTTON N., RAY S., SILICIANO R.F. (2000). A stable latent reservoir for HIV-1 in resting CD4(+) T lymphocytes in infected children. *J. Clin. Invest.* **105** (7), 995-1003.
- PIERSON T., MCARTHUR J., SILICIANO R.F. (2000). Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. *Annu. Rev. Immunol.* **18**, 665-708.
- POMERANTZ R.J. (2003). Reservoirs, sanctuaries, and residual disease: the hiding spots of HIV-1. *HIV Clin. Trials.* **4** (2), 137-143.
- RAMRATNAM B., MITTLER J.E., ZHANG L., BODEN D., HURLEY A., FANG F., MACKEN C.A., PERELSON A.S., MARKOWITZ M., HO D.D. (2000). The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. *Nat. Med.* **6** (1), 82-85.
- RAMRATNAM B., RIBEIRO R., HE T., CHUNG C., SIMON V., VANDERHOEVEN J., HURLEY A., ZHANG L., PERELSON A.S., HO D.D., MARKOWITZ M. (2004).

- Intensification of antiretroviral therapy accelerates the decay of the HIV-1 latent reservoir and decreases, but does not eliminate, ongoing virus replication. *J. Acquir. Immune Defic. Syndr.* **35** (1), 33-37.
- RE M.C., VITONE F., BON I., SCHIAVONE P., GIBELLINI D. (2006). Meaning of DNA detection during the follow-up of HIV-1 infected patients: a brief review. *New Microbiol.* **29** (2), 81-88.
- ROBINSON H.L., ZINKUS D.M. (1990). Accumulation of human immunodeficiency virus type 1 DNA in T cells: results of multiple infection events. *J. Virol.* **64** (10), 4836-4841.
- ROSENBERG E.S., ALTFELD M., POON S.H., PHILLIPS M.N., WILKES B.M., ELDRIDGE R.L., ROBBINS G.K., D'AQUILA R.T., GOULDER P.J., WALKER B.D. (2000). Immune control of HIV-1 after early treatment of acute infection. *Nature.* **407**, 523-526.
- ROUZIYOUX C., HUBERT J.B., BURGARD M., DEVEAU C., GOUARD C., BARY M., SERENI D., VIARD J.P., DELFRAISSY J.F., MEYER L. (2005). Early levels of HIV-1 DNA in peripheral blood mononuclear cells are predictive of disease progression independently of HIV-1 RNA levels and CD4+ T cell counts. *J. Infect. Dis.* **192** (1), 46-55.
- RUFF C.T., RAY S.C., KWON P., ZINN R., PENDLETON A., HUTTON N., ASHWORTH R., GANGE S., QUINN T.C., SILICIANO R.F., PERSAUD D. (2002). Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in paediatric patients with extensive antiretroviral exposure. *J. Virol.* **76** (18), 9481-9492.
- SARMATI L., ANDREONI C., NICASTRI E., TOMMASI C., BUONOMINI A., D'ETTORRE G., CORPOLONGO A., DORI L., MONTANO M., VOLPI A., NARCISO P., VULLO V., ANDREONI M. (2009). Prognostic factors of long-term CD4+count guided interruption of antiretroviral treatment. *J. Med. Virol.* **81** (3), 481-487.
- SEDAGHAT A.R., DINOSO J.B., SHEN L., WILKE C.O., SILICIANO R.F. (2008). Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle. *Proc. Natl. Acad. Sci. USA.* **105** (12), 4832-4837.
- SHARKEY M.E., TEO I., GREENOUGH T., SHAROVA N., LUZURIAGA K., SULLIVAN J.L., BUCY R.P., KOSTRIKIS L.G., HAASE A., VERYARD C., DAVARO R.E., CHEESEMAN S.H., DALY J.S., BOVA C., ELLISON R.T. 3RD, MADY B., LAI K.K., MOYLE G., NELSON M., GAZZARD B., SHAUNAK S., STEVENSON M. (2000). Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy. *Nat. Med.* **6**, 76-81.
- SHEN L., SILICIANO R.F. (2008). Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection. *J. Allergy. Clin. Immunol.* **122** (1), 22-28.
- SHIRAMIZU B., PAUL R., WILLIAMS A., SHIKUMA C., WATTERS M., GROVE J., VALCOUR V. (2007). HIV proviral DNA associated with decreased neuropsychological function. *J Neuropsychiatry Clin Neurosci.* **19** (2), 157-163.
- SHIRAMIZU B., WILLIAMS A.E., SHIKUMA C., VALCOUR V. (2009). Amount of HIV-DNA in peripheral blood mononuclear cells is proportional to the severity of HIV-1 associated neurocognitive disorders. *J. Neuropsychiatry Clin. Neurosci.* **21** (1), 68-74.
- SILICIANO J.D., KAJDAS J., FINZI D., QUINN T.C., CHADWICK K., MARGOLICK J.B., KOVACS C., GANGE S.J., SILICIANO R.F. (2003). Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. *Nat. Med.* **9** (6), 727-728.
- SILVA W.P., SANTOS D.E., LEAL E., BRUNSTEIN A., SUCUPIRA M.C., SABINO E.C., DIAZ R.S. (2006). Reactivation of ancestral strains of HIV-1 in the gp120 V3 env region in patients failing antiretroviral therapy and subjected to structured treatment interruption. *Virology.* **354** (1), 35-47.
- STEVENSON M., HAGGERTY S., LAMONICA C., MEIER C.M., WELCH S.K., WASIAK A.J. (1990). Integration is not necessary for expression of human immunodeficiency virus type 1 protein products. *J. Virol.* **64**, 2421-2425.
- STEVENSON M., STANWICK T., DEMPSEY M.P., LAONIC C.A. (1990). HIV-1 replication is controlled at the level of T cell activation and proviral integration. *EMBO J.* **9**, 1551-1560.
- STRAIN M.C., GÜNTARD H.F., HAVLIR D.V., IGNACIO C.C., SMITH D.M., LEIGH-BROWN A.J., MACARANAS T.R., LAM R.Y., DALY O.A., FISCHER M., OPRAVIL M., LEVINE H., BACHELER L., SPINA C.A., RICHMAN D.D., WONG J.K. (2003). Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic stability predicts lifelong persistence. *Proc. Natl. Acad. Sci. USA.* **100** (8), 4819-4824.
- STRAIN M.C., LITTLE S.J., DAAR E.S., HAVLIR D.V., GÜNTARD H.F., LAM R.Y., DALY O.A., NGUYEN J., IGNACIO C.C., SPINA C.A., RICHMAN D.D., WONG J.K. (2005). Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. *J. Infect. Dis.* **191** (9), 1410-1418.
- SWIGGARD W.J., BAYTOP C., YU J.J., DAI J., LI C., SCHRETZENMAIR R., THEODOSPOULOS T., O'DOHERTY U. (2005). Human immunodeficiency virus type 1 can establish latent infection in resting CD4+ T cells in the absence of activating stimuli. *J. Virol.* **79** (22), 14179-14188.
- TEO I., VERYARD C., BARNES H., AN S.F., JONES M., LANTOS P.L., LUTHERT P., SHAUNAK S. (1997). Circular forms of unintegrated human immunodeficiency virus type 1 DNA and high levels of viral protein expression: association with dementia and multinucleated giant cells in the brains of patients with AIDS. *J Virol.* **71** (4), 2928-2933.
- VANDERGRAAFF N., KUMAR R., BURRELL C.J., LI P. (2001). Kinetics of human immunodeficiency virus type 1 (HIV) DNA integration in acutely infected cells as

- determined using a novel assay for detection of integrated HIV DNA. *J. Virol.* **75**, 11253-11260.
- VIARD J.P., BURGARD M., HUBERT J.B., AARON L., RABIAN C., PERTUISET N., LOURENÇO M., ROTHSCHILD C., ROUZIUX C. (2004). Impact of 5 years of maximally successful highly active antiretroviral therapy on CD4 cell count and HIV-1 DNA level. *AIDS.* **18** (1), 45-49.
- WONG J.K., HEZAREH M., GÜNTARD H.F., HAVLIR D.V., IGNACIO C.C., SPINA C.A., RICHMAN D.D. (1997). Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. *Science.* **278** (5341), 1291-1295.
- WU Y. (2004). HIV-1 gene expression: lessons from provirus and non-integrated DNA. *Retrovirology.* 1-13.
- ZHANG L., RAMRATNAM B., TENNER-RACZ K., HE Y., VESANEN M., LEWIN S., TALAL A., RACZ P., PERELSON A.S., KORBER B.T., MARKOWITZ M., HO D.D. (1999). Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. *N. Engl. J. Med.* **340** (21), 1605-1613.

